fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg. - LARVOL DELTA

Impact of Fluticasone Propionate and Salmeterol Combined with Pulmonary Rehabilitation on Pulmonary Function, Exercise Tolerance, and Quality of Life in Elderly Patients with Stable Chronic Obstructive Pulmonary Disease. (PubMed, Br J Hosp Med (Lond)) - "The recurrence rate in the combined treatment group was significantly lower than in the pulmonary rehabilitation alone group (p = 0.018), with no significant difference in the incidence of adverse events between the two groups (p > 0.05). Conclusion Fluticasone propionate and salmeterol inhalation combined with pulmonary rehabilitation can reduce recurrence rates, and improve pulmonary function, inflammatory status, and exercise tolerance, thereby significantly enhancing the quality of life for elderly patients with stable COPD."

HEOR • Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • CXCL8 • IL6 • TNFA

Economic Evaluation of Single-Inhaler Extrafine Beclometasone Dipropionate/formoterol fumarate/glycopyrronium (Trimbow®) in Adult Patients with Uncontrolled Asthma in Mexico (ISPOR 2025) - "OBJECTIVES: Achieving optimal asthma control remains a global challenge, despite the availability of effective treatments for most adult patients. The extrafine SITT with BDP/FF/G is a dominant therapeutic option for adults with uncontrolled asthma in Mexico, delivering superior asthma control, significantly reducing exacerbations, and lowering annual per-patient costs compared to therapies currently used by IMSS."

Clinical • HEOR • Asthma • Immunology • Respiratory Diseases

Clinical Outcomes After Switching From Metered-Dose Inhaler Budesonide-Formoterol to Dry-Powder Inhaler Fluticasone-Salmeterol in a Nationwide Veteran Cohort (ATS 2025) - No abstract available

Clinical • Clinical data • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

ICS-LABA Fixed-Dose Combinations: Preferred Controller in 6-11-year-olds with Persistent Asthma. (PubMed, Int Arch Allergy Immunol) - "ICS-LABA fixed-dose combination therapies have been found to be more effective than ICS monotherapy in preventing asthma exacerbations in 6-11-year-old children with persistent asthma and could be recommended as the preferred controllers."

Journal • Asthma • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Impact of SMART with Budesonide and Formoterol vs. Traditional Asthma Therapy with Fluticasone and Salmeterol on COVID-19 Severity: A Retrospective Cohort Study (AAAAI-WAO 2025) - "The SMART group appeared to have lower frequency of severe COVID-19 infection compared to the group with traditional therapy (13.8% vs. 17.9%; p=0.084); however, no difference was found statistically in the crude analysis (RR 0.77, 95% CI 0.55-1.05) and in the adjusted analysis (1.01, 0.71-1.38). Conclusions SMART does not reduce COVID severity compared to the traditional therapy in treating moderate to severe asthma."

Retrospective data • Asthma • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Fatal Empyema Thoracis Caused by Nocardia otitidiscaviarum. (PubMed, Infect Drug Resist) - "We report an 81-year-old patient with chronic obstructive pulmonary disease treated by long-term inhalation of high-dose salmeterol fluticasone. The initial empirical anti-infection treatment proved ineffective, resulting in rapid disease progression before the confirmation of nocardiosis with empyema through cultures of pleural fluid and sputum...Therefore, the primary step in the management of the infection is timely diagnosis using different methods. Furthermore, the identification of the responsible strain followed by conducting drug sensitivity tests is paramount for the successful treatment of this disease."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock

Explore the application effect of acupoint massage combined with ear point pressing beans in the remission stage of asthma. (PubMed, Explore (NY)) - "Acupoint massage combined with ear point pressing beans has a good effect on the treatment of asthma remission and can effectively improve the quality of life, making it worthy of further promotion in clinical practice."

Journal • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis. (PubMed, Sci Rep) - "The objective of this study was to determine the comparative efficacy of extra-fine single-inhaler medium-dose (MD) or high-dose (HD) of beclometasone/formoterol/glycopyrronium bromide (BDP/FOR/GLY) compared to other triple therapies in patients whose asthma remains uncontrolled with MD or HD inhaled corticosteroids and long-acting β2-agonists...Among single-inhaler triple therapies, MD BDP/FOR/GLY significantly reduced the risk of severe exacerbations (RR [95% CrI] compared to MD fluticasone/umeclidinium/vilanterol: 0.65 [0.49, 0.89]), while HD BDP/FOR/GLY demonstrated an improved trend in reducing severe and moderate-to-severe exacerbations versus HD indacaterol acetate/glycopyrronium bromide/mometasone, fluticasone/umeclidinium/vilanterol, and salmeterol/fluticasone + tiotropium. HD BDP/FOR/GLY and HD BDP/FOR + tiotropium did not differ significantly. Compared to relevant single-inhaler triple therapies, MD and HD BDP/FOR/GLY are associated with a significant benefit..."

Clinical • Journal • Retrospective data • Review • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Development of Novel Fluticasone/Salmeterol/Tiotropium-Loaded Dry Powder Inhaler and Bioequivalence Assessment to Commercial Products in Rats. (PubMed, Pharmaceutics) - "Optimized FP/SX/TB-loaded DPI with HPMC capsule achieved bioequivalence in rat studies, suggesting its potential for improved patient compliance and therapeutic outcomes. This novel single-device DPI offers a promising alternative for triple therapy in pulmonary diseases."

Journal • Preclinical • Pulmonary Disease • Respiratory Diseases

Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs. (PubMed, BMC Pulm Med) - "This systematic review and meta-analysis concludes that UMEC and VI combinations are an efficacious treatment option for symptomatic COPD patients."

Clinical • Journal • Retrospective data • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (clinicaltrials.gov) - P3 | N=304 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Aug 2027 ➔ Feb 2029

Trial completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Effect of a formulary change from budesonideformoterol to fluticasonesalmeterol on chronic obstructive pulmonary disease control among Veterans at the Veterans Affairs Maryland Health Care System (ASHP 2024) - No abstract available

Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Correct use of inhalers for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Drugs for asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison chart: Some inhaled drugs for treatment of asthma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "As a result, the substantial impact of batch-to-batch variability on the study power and type I error of the PK BE study may pose significant challenges for the development of generic Advair Diskus due to its degree of PK batch-to-batch variability. Therefore, alternative PK BE study designs and guidelines are needed to adequately address the influence of batch-to-batch variability in products like Advair Diskus."

Journal • PK/PD data

Cost-Utility Analysis of Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate for Maintenance Therapy in Patients With Moderate-to-Severe Uncontrolled Asthma in China (ISPOR-EU 2024) - "This study aims to evaluate the cost-effectiveness of IND/GLY/MF compared to salmeterol/fluticasone+tiotropium bromide (SAL/FLU+TIO) and SAL/FLU, respectively, for the treatment of adult patients with uncontrolled moderate-to-severe asthma. The single-inhaler IND/GLY/MF offered better clinical efficacy and was considered cost-effective with increased QALY gain for the maintenance therapy in Chinese patients with moderate-to-severe uncontrolled asthma."

Clinical • HEOR • Asthma • Immunology • Respiratory Diseases

A service evaluation of digital assessment of lung function and ICS/LABA treatment among Irish Severe Asthma Centres (BTS WM 2024) - "The median age was 50 (16–74), 92 were prescribed Step 4 or higher ICS/LABA treatment, (10% salmeterol/fluticasone propionate, 17% formoterol/budesonide and 65% salmeterol/Fluticasone fumarate, 8% others)...Twenty eight percent of patients were uncontrolled and had good ICS/LABA treatment adherence, 30% were uncontrolled but had poor ICS/LABA treatment adherence, 30% were controlled and adherent, while 13% were controlled despite poor adherence, see figure 1 . Conclusion The data support a period of digital monitoring of peak flow and adherence to identify whether the cause of poor control and repeated exacerbations is refractory disease or poor adherence to ICS/LABA treatment."

Asthma • Immunology • Inflammation • Respiratory Diseases

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (clinicaltrials.gov) - P2 | N=1000 | Recruiting | Sponsor: Sanofi

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Real-world Effectiveness of Fluticasone/ Salmeterol (FP/SAL) in Uncontrolled Asthma with as-needed Regimen (KATRDIC 2024) - "Conclusions This study presents the real-world effectiveness of stepping up to FP/SAL PRD in achieving asthma control among patients with history of uncontrolled asthma on PRN regimen. Further clinical studies are required to validate these findings."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Asthma • Immunology • Respiratory Diseases

IMPACT OF HIGH-DOSE INHALED CORTICOSTEROIDS: A CASE OF AVASCULAR NECROSIS (ACAAI 2024) - "His fluticasonesalmeterol inhaler was subsequently decreased from 500mcg/50mcg to 250mcg/50 mcg twice daily...Following a thorough history and chart review, two possible culprits were identified in his AVN development: long-term high-dose ICS use and his 50-packyear smoking history, although the relationship between tobacco use and AVN remains controversial.3 It is worth considering dose reduction for patients on long-term ICS with symptoms concerning for AVN, particularly at high doses. Furthermore, early imaging can reduce both the risk of progression and the need for surgical intervention."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Orthopedics • Osteoarthritis • Pain • Respiratory Diseases • Rheumatology

Prevalence of Oral Candidiasis in Asthma and COPD Patients Using Inhaled Corticosteroids in the Philippine General Hospital Department of Out-patient Services. (PubMed, Acta Med Philipp) - "Increased prevalence was observed in adult females with asthma under low dose ICS therapy with Fluticasone/Salmeterol DPI for more than a year...It is also recommended to quantifiably measure patient compliance, inhalation technique and instruction, and its association to OC prevalence. Findings may be used to strengthen patient education, preventive measures, and disease management to facilitate improved compliance and effective treatment outcomes."

Journal • Asthma • Candidiasis • Chronic Obstructive Pulmonary Disease • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

PNEUMOCYSTIC JIROVECII: ALWAYS A DIFFERENTIAL (CHEST 2024) - "CASE PRESENTATION: A 52-year-old woman with a history of HIV on antiretroviral therapy (dolutegravir and rilpivirine), previously treated latent tuberculosis, tracheal stenosis and COPD on high dose inhaled fluticasone/salmeterol and tiotropium was evaluated for 3 weeks of progressive dyspnea...Given the acuity of her dyspnea which only partially improved with balloon dilatation, she was treated with oral trimethoprim-sulfamethoxazole for 21 days and ciprofloxacin for 14 days... PJP is an ubiquitous colonizer in the respiratory tract which may become pathogenic and cause clinical pneumonia in the setting of prolonged use of inhaled steroids, especially in HIV patients on protease-inhibitors, even in the setting of immune reconstitution and undetectable viral load."

Chronic Obstructive Pulmonary Disease • Cushing’s Disease • Endocrine Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Tuberculosis • CD4

CORN KERNEL ASPIRATION MIMICKING SEVERE PERSISTENT ASTHMA (CHEST 2024) - "CASE PRESENTATION: A 57-year-old female with a medical history pertinent for mild intermittent asthma that was previously well controlled on fluticasone/salmeterol and as-needed albuterol inhalers was seen in the office a week after being hospitalized for an asthma exacerbation...Tiotropium inhaler and Montelukast were added to her treatment regimen, and she was scheduled for a bronchoscopic evaluation of the endobronchial lesion... Our case highlights the importance of broadening differential diagnosis when a patient's asthma symptoms abruptly worsen, especially when bronchodilator and anti-inflammatory therapy fails."

Asthma • Cough • Immunology • Infectious Disease • Lung Cancer • Oncology • Pain • Pediatrics • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor

TACKLING THE DIFFICULTIES IN DIAGNOSING ASTHMA-COPD OVERLAP (ACO): EXPLORING THE DISTINCTIVE FEATURES OF ASTHMA-COPD OVERLAP (ACO) (CHEST 2024) - "She was seen for the first time at the pulmonary clinic in early July 2022, when she reported having required multiple courses of prednisone and a poor functional status. Spirometry at that visit showed FEV1 33%, FEV1/FVC 58% (Figure 4), and she was started on Fluticasone propionate and Salmeterol, one puff twice a day, and Tiotropium bromide... ACOS poses challenges due to its varied clinical manifestations arising from multiple underlying factors, further exacerbated by the limited research data. Nonetheless, precise identification of ACOS in patients is essential for devising personalized treatment plans focused on alleviating symptoms and minimizing exacerbations, ultimately enhancing the clinical management of individuals with Asthma-COPD Overlap."

Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Genetic Disorders • Hypertension • Immunology • Nicotine Addiction • Obesity • Respiratory Diseases • Tobacco Addiction